The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).

Authors

N. A. Pennell

Cleveland Clinic, Cleveland, OH

N. A. Pennell , J. W. Neal , R. Govindan , P. A. Janne , T. L. Evans , D. B. Costa , R. P. G. Rosovsky , M. Lanuti , C. G. Azzoli , L. V. Sequist

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

First Author: Joel W. Neal

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Common and rare EGFR mutations (EGFRm) in the RADIANT trial: Final follow-up with 5 year data.

First Author: Frances A. Shepherd

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303).

First Author: Karen L. Reckamp

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

First Author: Nathan A. Pennell